接受CAR T细胞治疗的多发性骨髓瘤患者临床结局的种族和民族差异
本研究汇总11家机构207例接受标准治疗伊达基奥仑赛的复发/难治多发性骨髓瘤患者数据,其中西班牙裔22例(11%)、非西班牙裔黑人36例(17%)、非西班牙裔白人149例(72%)。非西班牙裔黑人患者C反应蛋白中位数更高(1.0、0.8和3.5 mg/dL,P=0.02)且更易发生细胞因子释放综合征(77%、85%和97%,P=0.04);西班牙裔患者最佳总缓解率较低(59%对86%和86%,P=0.01),但无进展生存和总生存无种族和民族差异。
要点
- 非西班牙裔黑人患者细胞因子释放综合征发生率更高(97%对西班牙裔77%和非西班牙裔白人85%,P=0.04)。
- 西班牙裔患者最佳总缓解率较低(59%对非西班牙裔黑人86%和非西班牙裔白人86%,P=0.01)。
- 无进展生存和总生存无种族和民族差异。
核心结论
- 尽管伊达基奥仑赛安全性和缓解率存在种族和民族差异,研究结果鼓励在所有复发/难治多发性骨髓瘤患者中使用伊达基奥仑赛。
- 这些发现需在更大样本、更多样化的复发/难治多发性骨髓瘤患者中以更长随访时间确认。
研究设计与样本
- 本研究汇总11家机构207例接受标准治疗伊达基奥仑赛的复发/难治多发性骨髓瘤患者数据,其中28%为种族和民族少数群体。
- 纳入患者包括西班牙裔22例(11%)、非西班牙裔黑人36例(17%)和非西班牙裔白人149例(72%)。
主要发现
- 非西班牙裔黑人患者C反应蛋白中位数水平高于西班牙裔和非西班牙裔白人患者(分别为1.0、0.8和3.5 mg/dL,P=0.02)。
- 非西班牙裔黑人患者基线铁蛋白中位数分别为362.0、307.0和680.5(P=0.08)。
- 非西班牙裔黑人患者更易发生细胞因子释放综合征(分别为77%、85%和97%,P=0.04)。
- 西班牙裔患者最佳总缓解率(59%)低于非西班牙裔黑人(86%)和非西班牙裔白人(86%)(P=0.01)。
- 无进展生存和总生存无种族和民族差异。
临床怎么用
- 作者认为,尽管伊达基奥仑赛安全性和缓解率存在差异,研究结果鼓励在所有复发/难治多发性骨髓瘤患者中使用伊达基奥仑赛。
局限性
- 这些发现需在更大样本的多样化复发/难治多发性骨髓瘤患者中确认。
- 需更长的随访时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Idecabtagene vicleucel (ide-cel) was the first chimeric antigen receptor T-cell therapy to gain US Food and Drug Administration approval for patients with relapsed/refractory multiple myeloma (RRMM). The clinical outcomes of standard of care (SOC) ide-cel in racially and ethnically diverse populations have been understudied. This study pooled data from 207 patients with RRMM (28% patients of racial and ethnic minority groups) treated with SOC ide-cel across 11 institutions to examine racial and ethnic differences in the incidence of toxicities and adverse events, response to ide-cel, and survival. This study included 22 (11%) Hispanic, 36 (17%) non-Hispanic Black, and 149 (72%) non-Hispanic White patients with RRMM. Compared with Hispanic and non-Hispanic White patients, non-Hispanic Black patients had higher median levels of C-reactive protein (1.0, 0.8, and 3.5 mg/dL, respectively; P = .02) and baseline ferritin (362.0 vs 307.0 vs 680.5, respectively; P = .08) and were more likely to develop cytokine release syndrome (77%, 85%, and 97%, respectively; P = .04). Although best overall response rate was lower among Hispanic patients (59%) than among non-Hispanic Black (86%) and White patients (86%; P = .01), there were no racial and ethnic differences in progression-free or overall survival. We provide, to our knowledge, the first and largest investigation of clinical outcomes of SOC ide-cel by race and ethnicity. Despite differences in safety and response to ide-cel, our findings encourage the use of ide-cel in all patients with RRMM. These findings should be confirmed in larger samples of diverse patients with RRMM, with longer follow-up time.
引用
- Peres LC, Oswald LB, Dillard CM, et al. Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy. Blood Adv. 2024. PMID: 37855718. doi:10.1182/bloodadvances.2023010894
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。